Approximately 5–20% of PD patients carry a heterozygous GBA1 mutation (GBA-PD), differentiated by a 30–40% reduction in GCase activity, earlier disease onset including an increased risk for developing dementia with an up to five years earlier onset [12–23]. The gene discussed is GBA1; the disease is Parkinson disease.